Hank Pym does not enjoy the best reputation among his fellow heroes, but now Marvel is giving him one last shot at redemption ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Dyne Therapeutics Inc (Symbol: DYN) entered into oversold territory, hitting an RSI reading ...

Could this be the most technologically-advanced new van on sale? Quite possibly. Beneath the modern, but cutesy styling, this electric Farizon SV van hides some next-gen technology that’s barely ...

An all-new Volkswagen Transporter is a big deal – any all-new van is worth paying attention to given that commercial vehicles have longer lifecycles than their passenger-car cousins. However ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Thankfully, for those who want to avoid any unnecessary visits to the airport, the camper van is in the midst of something of a golden age. Today’s camper van, known to the heads as a Class B ...

If you have a standard driving licence you’re usually entitled to drive a van that weighs up to 3.5 tonnes including cargo and passengers. But as a heads-up, you may need to get a category C or D ...

There has been plenty of consternation over Green Bay Packers first round pick Lukas Van Ness and his first couple of years in the NFL, which have not exactly been spectacular. This led many to clamor ...

When a hatchback or family sedan simply won’t suffice for the school run, and an SUV isn’t a practical enough car, a van is the next step up in terms of hauling capabilities. Separated into ...

Dyne Therapeutics Inc. is back with another personnel announcement, appointing Erick Lucera as chief financial officer. Lucera comes to the Waltham company (Nasdaq: DYN) from Editas Medicine.

Sarepta’s news came as several companies—including Dyne Therapeutics, REGENXBIO and Genethon—presented new data on their next-generation exon-skipping therapies and gene therapies for Duchenne ...